Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04243057

Enrollment

5000

Registered

2020-01-27

Start date

2019-08-30

Completion date

2022-09-30

Last updated

2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Brief summary

This is a multicenter, two-way, non-intervention study. the main purpose: Understand the current status of diagnosis and treatment of cholangiocarcinoma patients in China and observe the effect of different treatment options on patient recurrence and long-term survival Secondary purpose: 1. Exploring the actual clinical treatment situation and its compliance with the existing diagnosis and treatment of bile duct cancer 2. Exploring the establishment of clinical research standard fields and standards for diagnosis and treatment of bile duct cancer

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. above the age of 18 years old, male or female 2. clinical diagnosis of patients with cholangiocarcinoma 3. Child-Pugh classification of A, B 4. Eastern Cooperative Oncology Group scoring system (ECOG) score of 0-2 points

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
RFSR	3 years	RFSR-Recurrence Free Survival Rate

Secondary

Measure	Time frame	Description
OS	3 years	OS-Overall Survival
RFS	3 years	RFS-Recurrence Free Survival

Countries

China

Contacts

Primary ContactXiaobin Feng, MD

fengxiaobin200708@aliyun.com+86 16601111975

Outcome results